![Michael J. Gresser](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Michael J. Gresser
Geen lopende functies
Loopbaan van Michael J. Gresser
Eerdere bekende functies van Michael J. Gresser
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Trillium Therapeutics, Inc. /Old/
![]() Trillium Therapeutics, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services Trillium Therapeutics Inc. (TTI), is a biopharmaceutical company specializing in the development of innovative therapies for the treatment of immune-mediated disorders. The Company's therapeutic approaches are aimed at restoring balance to the immune system in conditions associated with aberrant or harmful immune responses, such as autoimmune disease, inflammatory disorders, and cancer. TTI's objective is to create a broad and innovative pipeline of proprietary biologic product opportunities, as part of its overall strategy of building and solidifying its reputation as a premier R & D company. The company's business model is to identify therapeutic candidates that have shown promise in animal models and to rapidly advance these into clinical testing. TTI is concentrating its efforts on preclinical and early clinical drug development, with the primary objective of demonstrating safety and proof-of-principle in man. The company has chosen to establish development partnerships for some of its projects at a preclinical stage, and anticipates advancing several others into clinical development on its own. TTI has five scientific programs at various stages of preclinical testing. Two of its programs focus on the immunoregulatory protein CD200 and its receptor, a third targets the activating Fc receptor Fc RIIa (CD32a) and the final two involve the use of a growth factor in the prevention of necrotizing enterocolitis and the treatment of interstitial cystitis. | Directeur/Bestuurslid | 29-01-2010 | 06-06-2014 |
AMGEN INC. | Hoofd Techniek/Wetenschap/O&O | 01-01-2000 | 01-01-2006 |
Merck Frosst Canada Ltd.
![]() Merck Frosst Canada Ltd. Pharmaceuticals: MajorHealth Technology Merck Frosst Canada Ltd. is a Canadian pharmaceutical company that has been inventing medicines and vaccines for over 130 years. The company is based in Kirkland, Canada. The company's mission is to save and improve lives by bringing forward solutions for some of the world's most challenging diseases. | Corporate Officer/Principal | - | - |
Simon Fraser University | Corporate Officer/Principal | 01-01-1980 | - |
University of California, Los Angeles | Corporate Officer/Principal | - | - |
Oxford BioTherapeutics Ltd.
![]() Oxford BioTherapeutics Ltd. Pharmaceuticals: MajorHealth Technology Oxford BioTherapeutics Ltd. develops antibody-based medicines for oncology. The firm offers antibody-based cancer drugs with integrated diagnostics against novel targets. The company was founded by Christian Rohlff in 2003 and is headquartered in Abingdon, the United Kingdom. | Hoofd Techniek/Wetenschap/O&O | - | 08-09-2011 |
Corporate Officer/Principal | 08-09-2011 | - |
Opleiding van Michael J. Gresser
Brandeis University | Doctorate Degree |
Statistieken
Internationaal
Canada | 4 |
Verenigde Staten | 4 |
Verenigd Koninkrijk | 2 |
Operationeel
Corporate Officer/Principal | 4 |
Chief Tech/Sci/R&D Officer | 2 |
Doctorate Degree | 1 |
Sectoraal
Health Technology | 4 |
Consumer Services | 4 |
Commercial Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
AMGEN INC. | Health Technology |
Bedrijven in privébezit | 3 |
---|---|
Oxford BioTherapeutics Ltd.
![]() Oxford BioTherapeutics Ltd. Pharmaceuticals: MajorHealth Technology Oxford BioTherapeutics Ltd. develops antibody-based medicines for oncology. The firm offers antibody-based cancer drugs with integrated diagnostics against novel targets. The company was founded by Christian Rohlff in 2003 and is headquartered in Abingdon, the United Kingdom. | Health Technology |
Merck Frosst Canada Ltd.
![]() Merck Frosst Canada Ltd. Pharmaceuticals: MajorHealth Technology Merck Frosst Canada Ltd. is a Canadian pharmaceutical company that has been inventing medicines and vaccines for over 130 years. The company is based in Kirkland, Canada. The company's mission is to save and improve lives by bringing forward solutions for some of the world's most challenging diseases. | Health Technology |
Trillium Therapeutics, Inc. /Old/
![]() Trillium Therapeutics, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services Trillium Therapeutics Inc. (TTI), is a biopharmaceutical company specializing in the development of innovative therapies for the treatment of immune-mediated disorders. The Company's therapeutic approaches are aimed at restoring balance to the immune system in conditions associated with aberrant or harmful immune responses, such as autoimmune disease, inflammatory disorders, and cancer. TTI's objective is to create a broad and innovative pipeline of proprietary biologic product opportunities, as part of its overall strategy of building and solidifying its reputation as a premier R & D company. The company's business model is to identify therapeutic candidates that have shown promise in animal models and to rapidly advance these into clinical testing. TTI is concentrating its efforts on preclinical and early clinical drug development, with the primary objective of demonstrating safety and proof-of-principle in man. The company has chosen to establish development partnerships for some of its projects at a preclinical stage, and anticipates advancing several others into clinical development on its own. TTI has five scientific programs at various stages of preclinical testing. Two of its programs focus on the immunoregulatory protein CD200 and its receptor, a third targets the activating Fc receptor Fc RIIa (CD32a) and the final two involve the use of a growth factor in the prevention of necrotizing enterocolitis and the treatment of interstitial cystitis. | Commercial Services |
- Beurs
- Insiders
- Michael J. Gresser
- Ervaring